Effect of CR2093 on Tumor Growth
Author Information
Author(s): S.A. Watson, D.M. Crosbee, D.L. Morris, J.F.R. Robertson, F. Makovec, L.C. Rovati, J.D. Hardcastle
Primary Institution: University of Nottingham
Hypothesis
Can the gastrin receptor antagonist CR2093 inhibit the growth of gastrointestinal tumors?
Conclusion
CR2093 effectively reduced the growth of certain gastrointestinal tumor xenografts in mice.
Supporting Evidence
- CR2093 reduced gastrin-stimulated growth of AR42J and MKN45 xenografts.
- The drug did not inhibit the growth of C523 xenografts.
- CR2093 was administered intravenously at a dose of 40 mg/kg.
- Statistical tests showed significant differences in tumor growth between treated and control groups.
Takeaway
This study tested a drug called CR2093 to see if it could stop certain stomach and colon tumors from growing in mice, and it worked for some types.
Methodology
The study involved administering CR2093 to mice with xenografts of gastrointestinal tumors and measuring tumor growth.
Limitations
The drug did not inhibit the growth of all tumor types tested.
Participant Demographics
Male nude mice were used for the xenograft studies.
Statistical Information
P-Value
0.0109
Statistical Significance
p<0.05
Want to read the original?
Access the complete publication on the publisher's website